Frontline Success Bolsters IO ‘Backbone’ Hopes For GSK’s Jemperli
Also Rivals Keytruda In First-Line NSCLC
GSK’s PD-1 inhibitor will not be able to make up much ground on Keytruda, but new studies suggest it is a match for the market-leading PD-1 inhibitors.
You may also be interested in...
Blenrep’s withdrawal will add to GSK’s blockbuster drought, and hopes of separate trial success for the BCMA-targeting drug in earlier stage myeloma may now be harder to achieve.
GlaxoSmithKline is paying a 39% premium to buy Sierra Oncology and its myelofibrosis therapy momelotinib which is set to be filed shortly in the US on the back of a strong Phase III package.
Hopes are that the impact of the US FDA’s investigation into a small number of T-cell malignancies associated with CAR-T therapies will be small since the benefit/risk profile still looks sound.